ImageneBio, Inc.: Form 10-K for the period ended Dec 31, 2021
Filed with the SEC on Mar 17, 2022 and accepted by EDGAR at Mar 17, 2022, 06:31 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2021-01-01 to 2021-12-31 | $31.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 12 months2021-01-01 to 2021-12-31 | $47.1m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2021-01-01 to 2021-12-31 | −$34.1m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2021-01-01 to 2021-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2021-01-01 to 2021-12-31 | −$34.1m | us-gaap:NetIncomeLoss |
| Operating cash flow | 12 months2021-01-01 to 2021-12-31 | −$60.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2021-01-01 to 2021-12-31 | $1.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2021-12-31 | $232.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-12-31 | $236.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-12-31 | $247.9m | us-gaap:Assets |
| Current liabilities | At period end2021-12-31 | $27.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-12-31 | $40.0m | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-12-31 | $207.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-22-003998. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.